iBio
  • CDMO SERVICES
  • THERAPEUTICS AND VACCINES
    • Overview
    • Fibrosis
      • IBIO-100
    • COVID-19
      • IBIO-200 VLP Vaccine
      • IBIO-201 Subunit Vaccine
    • Classical Swine Fever
      • IBIO-400
    • Virus-Like Particles
    • LicKM
  • INVESTORS
  • CAREERS
Contact Us

Press Releases

Investors

Investors

  • Overview
  • Company Info
    • Profile
    • Management Team
  • News & Events
    • Press Releases
    • IR Calendar
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • IR Contact
    • Email Alerts
    • Investor FAQ
  • News & Events

  • Press Releases
  • IR Calendar
Sep 30, 2015 8:31am EDT

New Chinese iBioModulator(TM) Patent Joins iBio Vaccine Portfolio

Sep 21, 2015 8:31am EDT

iBio Anti-Fibrosis Portfolio Expanded to Include Orally Delivered Peptides

Sep 09, 2015 8:31am EDT

iBio Fibrosis Therapeutics Program Receives NIH Grant Support

Aug 11, 2015 8:31am EDT

iBio to Receive US Patent for Influenza Therapeutic

Jun 08, 2015 8:31am EDT

Three Recent iBioLaunch(TM) Platform Achievements to Be Presented at PBVAB 2015 Conference in Lausanne, Switzerland

May 04, 2015 8:31am EDT

Vaccine Improvement Patent Awarded to iBio

Apr 27, 2015 8:31am EDT

iBio Arranges Production of IBIO-CFB03 for Clinical Development With Caliber Biotherapeutics

Mar 30, 2015 8:31am EDT

iBio European Plague Vaccine Patent Emerges From Opposition Period

Feb 25, 2015 8:31am EST

iBio Adds Anthrax Antibodies to Product Pipeline

Feb 12, 2015 8:31am EST

iBio Receives US and European Patents for Protein Expression Technology

  • Previous
  • 1…
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

iBio, Inc.
iBio CDMO, LLC

8800 HSC Pkwy
Bryan, TX 77807


979.446.0027  
info@ibioinc.com

iBio Created with Sketch.

Privacy Policy

Copyright © iBio 2021